Drug Profile
Research programme: anti-RSV monoclonal antibodies - Biolex
Alternative Names: Anti-RSV antibodies research programme - Biolex; R-19Latest Information Update: 01 Oct 2012
Price :
$50
*
At a glance
- Originator Biolex
- Developer Biolex; Dow Chemical
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory syncytial virus infections
Most Recent Events
- 03 Jul 2012 Biolex files for Chapter 7 bankruptcy in the US Bankruptcy Court for the Middle District of North Carolina
- 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex
- 31 May 2002 Dow Chemical Company has started growing the first greenhouse plant lines to yield the RSV antibody product R-19